Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DWEJ | ISIN: US15117N6022 | Ticker-Symbol: CBO
Tradegate
06.06.25 | 15:31
1,330 Euro
+6,40 % +0,080
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMUNON INC Chart 1 Jahr
5-Tage-Chart
IMUNON INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,3501,40017:14
1,3501,40017:14

Aktuelle News zur IMUNON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiIMNN-001 shows promise in ovarian cancer treatment20
DiImunon, Inc.: IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study9
SaWhy Imunon, Inc. (IMNN) Surged Last Week30
30.05.Imunon, Inc. - S-1, General form for registration of securities3
30.05.Imunon Inc. droht Delisting von der Nasdaq wegen Compliance-Problemen26
IMUNON Aktie jetzt für 0€ handeln
28.05.Imunon, Inc.: IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules28
27.05.Imunon, Inc.: IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 202514
27.05.Imunon, Inc. - 8-K, Current Report3
26.05.IMUNON launches up to $9.75M securities offering19
24.05.Imunon, Inc.: IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules16
23.05.Imunon shares soar on promising ovarian cancer trial results36
23.05.Imunon, Inc.: IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer14
22.05.Imunon, Inc.: IMUNON Announces Withdrawal of Form S-1 Registration Statement304LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has...
► Artikel lesen
20.05.Imunon, Inc. - 8-K, Current Report6
15.05.IMUNON reports promising Phase 1 trial results for DNA vaccine5
15.05.Imunon, Inc.: IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19377Company's PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential applications...
► Artikel lesen
13.05.Imunon, Inc. - S-1/A, General form for registration of securities7
12.05.Imunon outlines 40% trial cost reduction and early readout potential as OVATION 3 Phase III launches6
12.05.Imunon, Inc. - 10-Q, Quarterly Report1
12.05.Imunon, Inc.: IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update368First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation...
► Artikel lesen
Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4